Charles Schwab’s Acorda Therapeutics ACOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-129
| Closed | -$11K | – | 3530 |
|
|
2020
Q4 | $11K | Hold |
129
| – | – | ﹤0.01% | 3391 |
|
|
2020
Q3 | $9K | Sell |
129
-1,473
| -92% | -$111K | ﹤0.01% | 3338 |
|
|
2020
Q2 | $142K | Sell |
1,602
-982
| -38% | -$104K | ﹤0.01% | 3212 |
|
|
2020
Q1 | $290K | Buy |
2,584
+39
| +2% | +$7.68K | ﹤0.01% | 2906 |
|
|
2019
Q4 | $624K | Buy |
2,545
+406
| +19% | +$102K | ﹤0.01% | 2739 |
|
|
2019
Q3 | $737K | Buy |
2,139
+95
| +5% | +$51.6K | ﹤0.01% | 2657 |
|
|
2019
Q2 | $1.88M | Sell |
2,044
-627
| -23% | -$770K | ﹤0.01% | 2392 |
|
|
2019
Q1 | $4.26M | Buy |
2,671
+12
| +0.5% | +$21.6K | ﹤0.01% | 2046 |
|
|
2018
Q4 | $4.97M | Sell |
2,659
-54
| -2% | -$118K | ﹤0.01% | 1905 |
|
|
2018
Q3 | $6.4M | Sell |
2,713
-45
| -2% | -$139K | ﹤0.01% | 1911 |
|
|
2018
Q2 | $9.5M | Buy |
2,758
+320
| +13% | +$980K | 0.01% | 1637 |
|
|
2018
Q1 | $6.92M | Sell |
2,438
-86
| -3% | -$258K | 0.01% | 1756 |
|
|
2017
Q4 | $6.5M | Buy |
2,524
+168
| +7% | +$478K | 0.01% | 1777 |
|
|
2017
Q3 | $6.69M | Sell |
2,356
-379
| -14% | -$998K | 0.01% | 1722 |
|
|
2017
Q2 | $6.46M | Sell |
2,735
-496
| -15% | -$983K | 0.01% | 1654 |
|
|
2017
Q1 | $8.14M | Buy |
3,231
+23
| +0.7% | +$66.2K | 0.01% | 1453 |
|
|
2016
Q4 | $7.24M | Sell |
3,208
-586
| -15% | -$1.39M | 0.01% | 1496 |
|
|
2016
Q3 | $9.51M | Sell |
3,794
-602
| -14% | -$1.8M | 0.01% | 1206 |
|
|
2016
Q2 | $13.5M | Buy |
4,396
+1,101
| +33% | +$3.58M | 0.02% | 873 |
|
|
2016
Q1 | $10.5M | Sell |
3,295
-1,278
| -28% | -$5.31M | 0.01% | 1019 |
|
|
2015
Q4 | $23.5M | Buy |
4,573
+143
| +3% | +$625K | 0.03% | 534 |
|
|
2015
Q3 | $14.1M | Sell |
4,430
-1
| -0% | -$3.88K | 0.02% | 747 |
|
|
2015
Q2 | $17.7M | Buy |
4,431
+80
| +2% | +$309K | 0.02% | 634 |
|
|
2015
Q1 | $17.4M | Buy |
4,351
+1,415
| +48% | +$6.48M | 0.02% | 627 |
|
|
2014
Q4 | $14.4M | Buy |
2,936
+1,834
| +166% | +$7.87M | 0.02% | 660 |
|
|
2014
Q3 | $4.48M | Buy |
1,102
+59
| +6% | +$221K | 0.01% | 1461 |
|
|
2014
Q2 | $4.22M | Buy |
1,043
+129
| +14% | +$526K | 0.01% | 1537 |
|
|
2014
Q1 | $4.16M | Buy |
914
+25
| +3% | +$101K | 0.01% | 1479 |
|
|
2013
Q4 | $3.12M | Sell |
889
-204
| -19% | -$795K | 0.01% | 1628 |
|
|
2013
Q3 | $4.65M | Sell |
1,093
-455
| -29% | -$1.96M | 0.01% | 1242 |
|
|
2013
Q2 | $6.45M | Buy |
+1,548
| New | +$6.37M | 0.01% | 836 |
|
Other funds holding ACOR
CCA
Charles Schwab's ACOR Position: Q1 2021 in Review
Charles Schwab sold out of Acorda Therapeutics (ACOR) in Q1 2021, closing a stake of 129 shares — an estimated $11K sold.
Charles Schwab first reported a position in ACOR in Q2 2013 and held it in 31 quarters. The position peaked at $23.5M in Q4 2015. 32 funds tracked by Wall St. Rank hold ACOR as of Q1 2021.
- Charles Schwab reported no remaining Acorda Therapeutics position as of Q1 2021 after selling out during the quarter.
- Charles Schwab sold 129 Acorda Therapeutics shares in Q1 2021, an estimated $11K.
- Charles Schwab first reported a position in Acorda Therapeutics in Q2 2013 and held it in 31 quarters.
- Charles Schwab's Acorda Therapeutics position peaked at $23.5M in Q4 2015.
- 32 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2021.
Based on Charles Schwab's 13F filing for Q1 2021, filed 17 May 2021.